医学
冲程(发动机)
生物标志物发现
临床实习
重症监护医学
标准化
生物标志物
神经学
生物信息学
物理疗法
蛋白质组学
计算机科学
生物
基因
操作系统
精神科
机械工程
工程类
生物化学
作者
Joseph Kamtchum‐Tatuene,Glen C. Jickling
标识
DOI:10.1007/s12017-019-08530-0
摘要
Biomarkers are objective indicators used to assess normal or pathological processes, evaluate responses to treatment and predict outcomes. Many blood biomarkers already guide decision-making in clinical practice. In stroke, the number of candidate biomarkers is constantly increasing. These biomarkers include proteins, ribonucleic acids, lipids or metabolites. Although biomarkers have the potential to improve the diagnosis and the management of patients with stroke, there is currently no marker that has demonstrated sufficient sensitivity, specificity, rapidity, precision, and cost-effectiveness to be used in the routine management of stroke, thus highlighting the need for additional work. A better standardization of clinical, laboratory and statistical procedures between centers is indispensable to optimize biomarker performance. This review focuses on blood biomarkers that have shown promise for translation into clinical practice and describes some newly reported markers that could add to routine stroke care. Avenues for the discovery of new stroke biomarkers and future research are discussed. The description of the biomarkers is organized according to their expected application in clinical practice: diagnosis, treatment decision, and outcome prediction.
科研通智能强力驱动
Strongly Powered by AbleSci AI